[
  {
    "ts": null,
    "headline": "How New Institutional Interest and Vaccine Approvals Could Reshape Zoetis’ (ZTS) Investment Narrative",
    "summary": "In 2025, Fundsmith Equity Fund began building a position in Zoetis, while the company reported third-quarter revenue growth and addressed safety concerns surrounding its Librela osteoarthritis treatment that some veterinarians continue to prescribe when they judge benefits to outweigh risks. At the same time, CEO Kristin Peck highlighted rising demand for livestock vaccines and a broad pipeline spanning chronic kidney disease, oncology, cardiology, obesity, metabolic disease, and anxiety in...",
    "url": "https://finnhub.io/api/news?id=5c6d55f23e0c141ec27a4015497ae05d5757693b30d8245f24b6a026aab9cd11",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768263276,
      "headline": "How New Institutional Interest and Vaccine Approvals Could Reshape Zoetis’ (ZTS) Investment Narrative",
      "id": 138083609,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ZTS",
      "source": "Yahoo",
      "summary": "In 2025, Fundsmith Equity Fund began building a position in Zoetis, while the company reported third-quarter revenue growth and addressed safety concerns surrounding its Librela osteoarthritis treatment that some veterinarians continue to prescribe when they judge benefits to outweigh risks. At the same time, CEO Kristin Peck highlighted rising demand for livestock vaccines and a broad pipeline spanning chronic kidney disease, oncology, cardiology, obesity, metabolic disease, and anxiety in...",
      "url": "https://finnhub.io/api/news?id=5c6d55f23e0c141ec27a4015497ae05d5757693b30d8245f24b6a026aab9cd11"
    }
  }
]